There is currently no cure for PBC and treatment goals include slowing disease ... For individuals living with hepatitis B or D, Gilead's focus on advancing medicines drives hope that today’s research ...

There is currently no cure for PBC and treatment goals include slowing disease ... For individuals living with hepatitis B or D, Gilead’s focus on advancing medicines drives hope that today’s research ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Biktarvy Demonstrates High Rates of Viral Suppression in People with HIV/HBV Coinfection ALLIANCE (NCT03547908 ... Landmark HIV Cure Clinical Trial Conducted in South Africa Results from the ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Analysts at William Blair have suggested that the market for an HBV cure could be around the same size as for hepatitis C virus, which peaked at around $10 billion a year but was a short-lived ...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.